The effect of systemic therapy on local-regional control in locally advanced breast cancer

Lori J. Pierce, Marc E Lippman, Noa Ben-Baruch, Sandra Swain, Joyce O'shaughnessy, Judith L. Bader, David Danforth, David Venzon, Kenneth H. Cowan

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

One hundred and seven patients with locally advanced breast cancer were prospectively referred for multimodality treatment on protocol using chemohormonal therapy to maximal response followed by local treatment and maintenance therapy. Forty-eight patients (45%) were diagnosed with Stage IIIA disease, 46 (43%) with Stage IIIB inflammatory cancer, and 13 (12%) with Stage IIIB non-inflammatory disease. Induction therapy consisted of cyclophosphamide, doxorubicin, methotrexate, and 5-fluorouracil with hormonal synchronization using tamoxifen and conjugated estrogens. Local treatment was determined by response to chemotherapy. Patients with a clinical partial response underwent mastectomy followed by local-regional radiotherapy while patients with a clinical complete response were biopsied for pathologic correlation. Those with residual disease received mastectomy followed by radiotherapy while those with a pathologic complete response received radiation only to the intact breast and regional nodes. With a median follow-up of 64 months, patients with IIIA disease had a significantly lower local-regional failure rate compared to IIIB inflammatory patients, with the 5-year actuarial local-regional failure rate as only site of first failure 3% for IIIA disease versus 21% for IIIB inflammatory cancer (p = .02), and local-regional failure as any component of first failure 12% versus 36% (p = .01), respectively. When local-regional failure was analyzed by repeat biopsy, 5 31 (16%) patients with a pathologic complete response treated with radiation only developed a local-regional failure versus 2 53 (4%) with residual disease treated with mastectomy and postoperative radiotherapy. The 5-year actuarial local-regional failure rate as first site of failure was 23% for radiation only versus 5% for mastectomy and post-operative radiotherapy (p = .07). The response to chemotherapy did not reliably predict local-regional control. Both relapse-free survival and overall survival were significantly better for IIIA versus IIIB patients; stratification by repeat biopsy did not, however, significantly affect either relapse-free or overall survival.

Original languageEnglish
Pages (from-to)949-960
Number of pages12
JournalInternational journal of radiation oncology, biology, physics
Volume23
Issue number5
DOIs
StatePublished - Jan 1 1992
Externally publishedYes

Fingerprint

breast
therapy
cancer
Breast Neoplasms
Mastectomy
Radiotherapy
radiation therapy
Therapeutics
Radiation
chemotherapy
Survival
radiation
Biopsy
Conjugated (USP) Estrogens
Recurrence
Drug Therapy
estrogens
Tamoxifen
Clinical Protocols
Methotrexate

Keywords

  • Breast cancer
  • Local-regional control
  • Locally advanced
  • Radiation Therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Pierce, L. J., Lippman, M. E., Ben-Baruch, N., Swain, S., O'shaughnessy, J., Bader, J. L., ... Cowan, K. H. (1992). The effect of systemic therapy on local-regional control in locally advanced breast cancer. International journal of radiation oncology, biology, physics, 23(5), 949-960. https://doi.org/10.1016/0360-3016(92)90899-S

The effect of systemic therapy on local-regional control in locally advanced breast cancer. / Pierce, Lori J.; Lippman, Marc E; Ben-Baruch, Noa; Swain, Sandra; O'shaughnessy, Joyce; Bader, Judith L.; Danforth, David; Venzon, David; Cowan, Kenneth H.

In: International journal of radiation oncology, biology, physics, Vol. 23, No. 5, 01.01.1992, p. 949-960.

Research output: Contribution to journalArticle

Pierce, LJ, Lippman, ME, Ben-Baruch, N, Swain, S, O'shaughnessy, J, Bader, JL, Danforth, D, Venzon, D & Cowan, KH 1992, 'The effect of systemic therapy on local-regional control in locally advanced breast cancer', International journal of radiation oncology, biology, physics, vol. 23, no. 5, pp. 949-960. https://doi.org/10.1016/0360-3016(92)90899-S
Pierce, Lori J. ; Lippman, Marc E ; Ben-Baruch, Noa ; Swain, Sandra ; O'shaughnessy, Joyce ; Bader, Judith L. ; Danforth, David ; Venzon, David ; Cowan, Kenneth H. / The effect of systemic therapy on local-regional control in locally advanced breast cancer. In: International journal of radiation oncology, biology, physics. 1992 ; Vol. 23, No. 5. pp. 949-960.
@article{fe4aa443ba0841c3bcdbe297c1302f8b,
title = "The effect of systemic therapy on local-regional control in locally advanced breast cancer",
abstract = "One hundred and seven patients with locally advanced breast cancer were prospectively referred for multimodality treatment on protocol using chemohormonal therapy to maximal response followed by local treatment and maintenance therapy. Forty-eight patients (45{\%}) were diagnosed with Stage IIIA disease, 46 (43{\%}) with Stage IIIB inflammatory cancer, and 13 (12{\%}) with Stage IIIB non-inflammatory disease. Induction therapy consisted of cyclophosphamide, doxorubicin, methotrexate, and 5-fluorouracil with hormonal synchronization using tamoxifen and conjugated estrogens. Local treatment was determined by response to chemotherapy. Patients with a clinical partial response underwent mastectomy followed by local-regional radiotherapy while patients with a clinical complete response were biopsied for pathologic correlation. Those with residual disease received mastectomy followed by radiotherapy while those with a pathologic complete response received radiation only to the intact breast and regional nodes. With a median follow-up of 64 months, patients with IIIA disease had a significantly lower local-regional failure rate compared to IIIB inflammatory patients, with the 5-year actuarial local-regional failure rate as only site of first failure 3{\%} for IIIA disease versus 21{\%} for IIIB inflammatory cancer (p = .02), and local-regional failure as any component of first failure 12{\%} versus 36{\%} (p = .01), respectively. When local-regional failure was analyzed by repeat biopsy, 5 31 (16{\%}) patients with a pathologic complete response treated with radiation only developed a local-regional failure versus 2 53 (4{\%}) with residual disease treated with mastectomy and postoperative radiotherapy. The 5-year actuarial local-regional failure rate as first site of failure was 23{\%} for radiation only versus 5{\%} for mastectomy and post-operative radiotherapy (p = .07). The response to chemotherapy did not reliably predict local-regional control. Both relapse-free survival and overall survival were significantly better for IIIA versus IIIB patients; stratification by repeat biopsy did not, however, significantly affect either relapse-free or overall survival.",
keywords = "Breast cancer, Local-regional control, Locally advanced, Radiation Therapy",
author = "Pierce, {Lori J.} and Lippman, {Marc E} and Noa Ben-Baruch and Sandra Swain and Joyce O'shaughnessy and Bader, {Judith L.} and David Danforth and David Venzon and Cowan, {Kenneth H.}",
year = "1992",
month = "1",
day = "1",
doi = "10.1016/0360-3016(92)90899-S",
language = "English",
volume = "23",
pages = "949--960",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - The effect of systemic therapy on local-regional control in locally advanced breast cancer

AU - Pierce, Lori J.

AU - Lippman, Marc E

AU - Ben-Baruch, Noa

AU - Swain, Sandra

AU - O'shaughnessy, Joyce

AU - Bader, Judith L.

AU - Danforth, David

AU - Venzon, David

AU - Cowan, Kenneth H.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - One hundred and seven patients with locally advanced breast cancer were prospectively referred for multimodality treatment on protocol using chemohormonal therapy to maximal response followed by local treatment and maintenance therapy. Forty-eight patients (45%) were diagnosed with Stage IIIA disease, 46 (43%) with Stage IIIB inflammatory cancer, and 13 (12%) with Stage IIIB non-inflammatory disease. Induction therapy consisted of cyclophosphamide, doxorubicin, methotrexate, and 5-fluorouracil with hormonal synchronization using tamoxifen and conjugated estrogens. Local treatment was determined by response to chemotherapy. Patients with a clinical partial response underwent mastectomy followed by local-regional radiotherapy while patients with a clinical complete response were biopsied for pathologic correlation. Those with residual disease received mastectomy followed by radiotherapy while those with a pathologic complete response received radiation only to the intact breast and regional nodes. With a median follow-up of 64 months, patients with IIIA disease had a significantly lower local-regional failure rate compared to IIIB inflammatory patients, with the 5-year actuarial local-regional failure rate as only site of first failure 3% for IIIA disease versus 21% for IIIB inflammatory cancer (p = .02), and local-regional failure as any component of first failure 12% versus 36% (p = .01), respectively. When local-regional failure was analyzed by repeat biopsy, 5 31 (16%) patients with a pathologic complete response treated with radiation only developed a local-regional failure versus 2 53 (4%) with residual disease treated with mastectomy and postoperative radiotherapy. The 5-year actuarial local-regional failure rate as first site of failure was 23% for radiation only versus 5% for mastectomy and post-operative radiotherapy (p = .07). The response to chemotherapy did not reliably predict local-regional control. Both relapse-free survival and overall survival were significantly better for IIIA versus IIIB patients; stratification by repeat biopsy did not, however, significantly affect either relapse-free or overall survival.

AB - One hundred and seven patients with locally advanced breast cancer were prospectively referred for multimodality treatment on protocol using chemohormonal therapy to maximal response followed by local treatment and maintenance therapy. Forty-eight patients (45%) were diagnosed with Stage IIIA disease, 46 (43%) with Stage IIIB inflammatory cancer, and 13 (12%) with Stage IIIB non-inflammatory disease. Induction therapy consisted of cyclophosphamide, doxorubicin, methotrexate, and 5-fluorouracil with hormonal synchronization using tamoxifen and conjugated estrogens. Local treatment was determined by response to chemotherapy. Patients with a clinical partial response underwent mastectomy followed by local-regional radiotherapy while patients with a clinical complete response were biopsied for pathologic correlation. Those with residual disease received mastectomy followed by radiotherapy while those with a pathologic complete response received radiation only to the intact breast and regional nodes. With a median follow-up of 64 months, patients with IIIA disease had a significantly lower local-regional failure rate compared to IIIB inflammatory patients, with the 5-year actuarial local-regional failure rate as only site of first failure 3% for IIIA disease versus 21% for IIIB inflammatory cancer (p = .02), and local-regional failure as any component of first failure 12% versus 36% (p = .01), respectively. When local-regional failure was analyzed by repeat biopsy, 5 31 (16%) patients with a pathologic complete response treated with radiation only developed a local-regional failure versus 2 53 (4%) with residual disease treated with mastectomy and postoperative radiotherapy. The 5-year actuarial local-regional failure rate as first site of failure was 23% for radiation only versus 5% for mastectomy and post-operative radiotherapy (p = .07). The response to chemotherapy did not reliably predict local-regional control. Both relapse-free survival and overall survival were significantly better for IIIA versus IIIB patients; stratification by repeat biopsy did not, however, significantly affect either relapse-free or overall survival.

KW - Breast cancer

KW - Local-regional control

KW - Locally advanced

KW - Radiation Therapy

UR - http://www.scopus.com/inward/record.url?scp=0026728754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026728754&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(92)90899-S

DO - 10.1016/0360-3016(92)90899-S

M3 - Article

C2 - 1639655

AN - SCOPUS:0026728754

VL - 23

SP - 949

EP - 960

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -